Vor Biopharma Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
VOR$19.98+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| (in thousands, except share and per share amounts) | 2025 | 2024 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $396,486 | $81,949 |
| Marketable securities | 58,722 | 9,977 |
| Prepaid expenses | 1,152 | 4,201 |
| Other current assets | 1,745 | 380 |
| Total current assets | 458,105 | 96,507 |
| Restricted cash equivalents | 168 | 2,413 |
| Property and equipment, net | 533 | 6,581 |
| Operating lease right-of-use assets | 2,936 | 35,007 |
| Other assets | 2,384 | 2,383 |
| Total assets | $464,126 | $142,891 |
| Liabilities and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $5,127 | $1,505 |
| Accrued liabilities | 19,764 | 12,892 |
| Operating lease liabilities | 280 | 4,215 |
| Total current liabilities | 25,171 | 18,612 |
| Non-current liabilities: | ||
| Operating lease liabilities—non-current | 2,720 | 27,615 |
| Warrant liabilities | 600,547 | — |
| Total liabilities | 628,438 | 46,227 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.0001 par value; 800,000,000 and 400,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 38,720,196 and 6,238,799 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 18 | 13 |
| Additional paid-in capital | 988,604 | 553,623 |
| Accumulated other comprehensive income | 41 | 22 |
| Accumulated deficit | (1,152,975) | (456,994) |
| Total stockholders’ equity (deficit) | (164,312) | 96,664 |
| Total liabilities and stockholders’ equity (deficit) | $464,126 | $142,891 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.